 |
市场调查报告书
商品编码
1890927
基因静默市场：按类型、按组件、按应用、按治疗领域、按技术、按给药方式、按最终用户、按地区划分Gene Silencing Market, By Type, By Component, By Application, By Therapeutic Area, By Technology, By Delivery Method, By End User, By Geography |
||||||
基因静默市场预计在 2025 年达到 112.1 亿美元，预计到 2032 年将达到 278.8 亿美元，2025 年至 2032 年的复合年增长率为 13.9%。
| 报告覆盖范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2024 | 2025年市场规模： | 112.1亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2025年至2032年 |
| 预测期（2025-2032年）复合年增长率： | 13.90% | 2032 年的预测值： | 278.8亿美元 |
全球基因静默市场是生物技术和製药行业中一个快速发展的领域，涵盖了靶向和调控特定基因表现的创新治疗方法。基因静默，也称为RNA干扰（RNAi）或基因敲低，涉及复杂的分子机制，可透过多种调查方法抑製或降低目标基因的表达，包括小干扰RNA（siRNA）、微型RNA （miRNA）、反义寡核苷酸和基于CRISPR的技术。
由于遗传性疾病、癌症、心血管疾病和神经系统疾病的日益增多，这些疾病都需要精准医疗，因此基因沉默市场正蓬勃发展。这项技术为治疗过去难以攻克的疾病提供了前所未有的机会，它能够特异性定序致病基因，同时最大限度地减少脱靶效应。主要的製药、生物技术和研究机构正在大力投资基因静默平台，以开发下一代疗法。该市场涵盖多种递送系统，包括脂质奈米颗粒、病毒载体和基于偶联物的递送机制，这些系统能够提高基因静默剂的稳定性和生物利用度。随着法规结构的不断完善和对这些创新治疗方法的支持，基因静默市场预计将在多个治疗领域革新治疗模式，在全球创造巨大的商业机会，并满足尚未满足的医疗需求。
市场动态
全球基因静默市场受多种强劲因素驱动。全球遗传性疾病和慢性疾病的日益普遍，使得针对能够特异性调控致病基因的标靶治疗介入措施的需求显着增长。越来越多的RNAi疗法已通过核准上市，例如patisiran和givosiran，证明了基因静默技术的临床潜力，并刺激了整个製药业的进一步投资和研发活动。递送系统技术的进步，特别是脂质奈米颗粒和组织特异性标靶化机制，显着提高了治疗效果并降低了副作用，使基因静默疗法更容易临床应用。然而，该市场也面临诸多限制因素。这些因素包括基因静默疗法的高昂研发成本、需要专业设施和技术专长的复杂生产工艺，以及严格的监管要求，这些都会延长研发週期并增加企业的财务风险。
此外，脱靶效应、免疫抗原性问题以及向特定组织的递送效率等挑战仍然是广泛应用的技术障碍。儘管有这些局限性，但随着应用范围从罕见疾病扩展到心血管、代谢和肿瘤等更常见的疾病，巨大的机会正在涌现。人们对个人化医疗和精准治疗日益增长的兴趣为基因静默技术创造了有利条件。同时，製药公司和生物技术公司之间日益密切的合作正在促进知识共用并加速产品开发。此外，新兴市场随着医疗基础设施的完善和创新治疗方法监管途径的建立，蕴藏着巨大的未开发潜力。这为基因静默市场在各个治疗领域实现持续成长和创新铺平了道路。
本次调查的主要特点
- 本报告对全球基因静默市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）内的市场规模（十亿美元）和復合年增长率（%）。
- 它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
- 该研究还提供了有关市场驱动因素、阻碍因素、机会、新产品发布或核准、市场趋势、区域展望以及主要参与者采取的竞争策略的重要见解。
- 该报告根据以下参数对全球基因静默市场的主要参与者进行了分析：公司概况、产品系列、主要特征、财务表现和策略。
- 本报告的研究结果将使负责人和经营团队能够就即将推出的产品、类型升级、市场扩张和行销策略做出明智的决策。
- 这份全球基因静默市场报告的目标受众是该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 相关人员可以透过各种用于分析全球基因静默市场的策略矩阵轻鬆做出决策。
目录
第一章 研究目标与前提条件
- 调查目的
- 先决条件
- 简称
第二章 市场范围
- 报告概述
- 市场定义和范围
- 执行摘要
第三章 市场动态、监理及趋势分析
- 市场动态
- 司机
- 抑制因素
- 机会
- 影响分析
- 重大进展
- 法规环境
- 产品上市及核准
- PEST分析
- 波特分析
- 併购趋势
- 产业趋势
4. 2020-2032年全球基因静默市场（依类型划分）
- 转录后
- 转录
5. 2020-2032年全球基因静默市场（依组件划分）
- 产品（试剂、试剂盒、设备）
- 服务
6. 2020-2032年全球基因静默市场（依应用领域划分）
- 功能基因体学
- 药物发现标靶检验
- 疾病模型
- 治疗方法研发
- 优化生物生产
7. 2020-2032年全球基因静默市场（依治疗领域划分）
- 肿瘤学
- 遗传性疾病
- 感染疾病
- 心血管疾病
- 神经系统疾病
- 代谢性疾病
- 自体免疫疾病
- 眼科疾病
8. 2020-2032年全球基因静默市场（依技术划分）
- RNA干扰（RNAi）
- 反义寡核苷酸（ASO）
- 基于CRISPR的基因静默
- siRNA
- shRNA
- 微型RNA
- 基于DNA甲基化的定序
- 基于组蛋白修饰的定序
9. 2020-2032年全球基因静默市场（以递送方式划分）
- 病毒载体递送
- 非病毒载体递送
- 脂质奈米颗粒
- 电穿孔
- 物理方法（显微注射、基因枪、超音波）
10. 2020-2032年全球基因静默市场（依最终用户划分）
- 製药和生物技术公司
- 学术和研究机构
- 合约研究组织（CRO）
- 诊断实验室
- 政府和非营利研究机构
11. 2020-2032年全球基因静默市场（按地区划分）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十二章 竞争格局
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies Inc.
- Danaher Corporation
- Bio Rad Laboratories Inc.
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals Inc.
- Sarepta Therapeutics Inc.
- Arbutus Biopharma Corporation
- Wave Life Sciences Ltd.
- Moderna Inc.
- BioNTech SE
第十三章 分析师建议
- 机会
- 分析师观点
- Coherent Opportunity Map
第十四章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Gene Silencing Market is estimated to be valued at USD 11.21 Bn in 2025 and is expected to reach USD 27.88 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 11.21 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 13.90% | 2032 Value Projection: | USD 27.88 Bn |
The global gene silencing market represents a rapidly evolving segment within the biotechnology and pharmaceutical industries, encompassing innovative therapeutic approaches that target specific genes to modulate their expression. Gene silencing, also known as RNA interference (RNAi) or gene knockdown, involves sophisticated molecular mechanisms that prevent or reduce the expression of target genes through various methodologies including small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, and CRISPR-based technologies.
This market has gained substantial momentum due to increasing prevalence of genetic disorders, cancer, cardiovascular diseases, and neurological conditions that require precision medicine approaches. The technology offers unprecedented opportunities for treating previously undruggable targets by specifically silencing disease-causing genes while minimizing off-target effects. Major pharmaceutical companies, biotechnology firms, and research institutions are heavily investing in gene silencing platforms to develop next-generation therapeutics. The market encompasses various delivery systems including lipid nanoparticles, viral vectors, and conjugate-based delivery mechanisms that enhance the stability and bioavailability of gene silencing agents. As regulatory frameworks continue to evolve and support these innovative therapies, the gene silencing market is positioned to transform treatment paradigms across multiple therapeutic areas, driving significant commercial opportunities and addressing critical unmet medical needs globally.
Market Dynamics
The global gene silencing market is propelled by several compelling drivers, including the escalating prevalence of genetic disorders and chronic diseases worldwide, which creates substantial demand for targeted therapeutic interventions that can specifically modulate disease-causing genes. The increasing success of approved RNAi therapeutics such as patisiran and givosiran has validated the clinical potential of gene silencing technologies, encouraging greater investment and development activities across the pharmaceutical industry. Technological advancements in delivery systems, particularly lipid nanoparticles and tissue-specific targeting mechanisms, have significantly improved the therapeutic efficacy and reduced adverse effects, making gene silencing approaches more viable for clinical applications. However, the market faces notable restraints including high development costs associated with gene silencing therapies, complex manufacturing processes requiring specialized facilities and expertise, and stringent regulatory requirements that extend development timelines and increase financial risks for companies.
Additionally, challenges related to off-target effects, immunogenicity concerns, and delivery efficiency to specific tissues continue to pose technical barriers for widespread adoption. Despite these constraints, substantial opportunities emerge from expanding applications beyond rare diseases into more prevalent conditions such as cardiovascular diseases, metabolic disorders, and oncology indications. The growing emphasis on personalized medicine and precision therapeutics creates favorable conditions for gene silencing technologies, while increasing collaborations between pharmaceutical companies and biotechnology firms facilitate knowledge sharing and accelerate product development. Furthermore, emerging markets present untapped potential as healthcare infrastructure improves and regulatory pathways for innovative therapies become more established, positioning the gene silencing market for sustained growth and innovation across diverse therapeutic landscapes.
Key Features of the Study
- This report provides in-depth analysis of the global gene silencing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global gene silencing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Danaher Corporation, Bio Rad Laboratories Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Dicerna Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arbutus Biopharma Corporation, Wave Life Sciences Ltd., Moderna Inc., and BioNTech SE
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global gene silencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gene silencing market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Post-Transcriptional
- Transcriptional
- Component Insights (Revenue, USD Bn, 2020 - 2032)
- Product (Reagents, Kits, Instruments)
- Services
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Functional Genomics
- Drug Target Validation
- Disease Modeling
- Therapeutic Development
- Bioproduction Optimization
- Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Genetic Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Metabolic Disorders
- Autoimmune Disorders
- Ophthalmic Diseases
- Technology Insights (Revenue, USD Bn, 2020 - 2032)
- RNA Interference (RNAi)
- Antisense Oligonucleotides (ASOs)
- CRISPR-based Gene Silencing
- siRNA
- shRNA
- miRNA
- DNA Methylation-based Silencing
- Histone Modification-based Silencing
- Delivery Method Insights (Revenue, USD Bn, 2020 - 2032)
- Viral Vector Delivery
- Non-Viral Vector Delivery
- Lipid Nanoparticles
- Electroporation
- Physical Methods (Microinjection, Gene Gun, Ultrasound)
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Pharmaceutical and Biotech Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Diagnostic Laboratories
- Government and Non-Profit Research Bodies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies Inc.
- Danaher Corporation
- Bio Rad Laboratories Inc.
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals Inc.
- Sarepta Therapeutics Inc.
- Arbutus Biopharma Corporation
- Wave Life Sciences Ltd.
- Moderna Inc.
- BioNTech SE
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Gene Silencing Market, By Type
- Global Gene Silencing Market, By Component
- Global Gene Silencing Market, By Application
- Global Gene Silencing Market, By Therapeutic Area
- Global Gene Silencing Market, By Technology
- Global Gene Silencing Market, By Delivery Method
- Global Gene Silencing Market, By End User
- Global Gene Silencing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Gene Silencing Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Post-Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Gene Silencing Market, By Component, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Product (Reagents, Kits, Instruments)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Gene Silencing Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Functional Genomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drug Target Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Therapeutic Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bioproduction Optimization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Gene Silencing Market, By Therapeutic Area, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Gene Silencing Market, By Technology, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- RNA Interference (RNAi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antisense Oligonucleotides (ASOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- CRISPR-based Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- siRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- shRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- miRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- DNA Methylation-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Histone Modification-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Gene Silencing Market, By Delivery Method, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lipid Nanoparticles
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Electroporation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Physical Methods (Microinjection, Gene Gun, Ultrasound)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Gene Silencing Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical and Biotech Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Government and Non-Profit Research Bodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Gene Silencing Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bio Rad Laboratories Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alnylam Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arrowhead Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Silence Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dicerna Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sarepta Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arbutus Biopharma Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Wave Life Sciences Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Moderna Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
基因表现分析市场规模、份额和成长分析（按产品、製程、产能、技术、应用和地区划分）－产业预测，2026-2033年
基因表现市场－全球产业规模、份额、趋势、机会及预测，依製程、产品、产能、应用、技术、地区及竞争格局划分，2020-2030年预测
基因表现市场按产品类型、应用、技术、工作流程步骤、样本类型、最终用户和地区划分
全球基因静默市场：预测至2032年－依产品/服务、机制、技术、应用、最终使用者及地区进行分析
基因静默市场分析及预测（至2034年）：类型、产品、服务、技术、应用、最终用户、组件、流程、模式与阶段
光遗传学市场按产品类型、技术、应用和最终用户划分－2025-2032年全球预测基因分析市场按技术、应用、产品类型和最终用户划分－2025-2032年全球预测基因表现分析市场按产品类型、应用、技术、最终用户和疾病类型划分－2025-2032年全球预测萤光素酶检测市场按产品类型、检测类型、检测仪器、技术、研究领域、应用和最终用户划分－2025-2032 年全球预测农业生物技术基因表现分析市场（按产品类型、技术、作物类型、应用和最终用户划分）—2025-2030 年全球预测